Phase I Dose-Escalation Study Of Brentuximab-Vedotin Combined With Dexamethasone, High-Dose Cytarabine And Cisplatin, As Salvage Treatment In Relapsed/Refractory Classical Hodgkin Lymphoma: The Hovon/Llpc Transplant Brave Study

Anton Hagenbeek,Hans Mooij,Josee Zijlstra,Pieternella Lugtenburg,Gustaaf Van Imhoff,Marcel Nijland,Sanne Tonino,Martin Hutchings, Marjolein Spiering,Roberto Liu,Harm Van Tinteren,Marie Jose Kersten

HAEMATOLOGICA（2019）

引用 19|浏览34

暂无评分

摘要

Clinical activity of brentuximab vedotin (BV), an anti-CD30 antibody-drug conjugate, has been demonstrated in relapsed/refractory classical Hodgkin Lymphoma (R/R cHL) in pivotal phase I and phase II studies.[1][1],[2][2] Adverse events ascribed to BV as single agent are mostly mild and reversible.[3

查看译文

关键词

Conditioning Regimen,Hodgkin's Lymphoma,Molecular Pharmacology

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要